Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence?
- 1 July 2005
- journal article
- Published by Elsevier in Value in Health
- Vol. 8 (4) , 433-446
- https://doi.org/10.1111/j.1524-4733.2005.00033.x
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questionsHealth Economics, 2004
- Network meta‐analysis for indirect treatment comparisonsStatistics in Medicine, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- BAYESIAN VALUE-OF-INFORMATION ANALYSISInternational Journal of Technology Assessment in Health Care, 2001
- Carrier Screening for Cystic FibrosisMedical Decision Making, 1998
- Sensitivity Analysis and the Expected Value of Perfect InformationMedical Decision Making, 1998
- Meta-analysis of Multitreatment StudiesMedical Decision Making, 1998
- The Value of Improved National Exposure Information for Perchloroethylene (Perc): A Case Study for Dry CleanersRisk Analysis, 1997
- An economic approach to clinical trial design and research priority-settingHealth Economics, 1996
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994